Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

There is a 'valley of death' in European research and innovation, says CEO of Novo Nordisk Foundation ...

IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

Denmark's Prime Minister Mette Frederiksen had summoned business leaders after speaking on Wednesday with U.S.

Medicare released its next target list of 15 drugs to negotiate prices of, including Novo Nordisk's blockbuster GLP-1 drugs.

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...